Neuraly announces topline results of their randomized, double-blind, placebo-controlled trial designed to assess safety, tolerability, & efficacy of their GLP-1 receptor agonist NLY01 in 255 individuals with early, untreated Parkinsons.
- The primary endpoint, change from baseline in the sum of MDS-UPDRS Parts II and III after 36 weeks of NLY01 treatment, compared with placebo, did not reach statistical significance.
* Age was identified as a significant factor in response. Statistically significant and dose-related improvements in UPDRS Parts II + III were observed in patients under the age of 60.
If the hypothesis is that these drugs are disease modifying, then one has to wonder what kind of difference you should expect between the modified and unmodified after less than 9 months in a group of PWPs with 'early, untreated Parkinsons'. Early PD can be quite stable for longer than 9 months at least in any manner than can currently be reliably measured.
Agreed. Exenatide trial (similar drug) is 2 years so I believe that should be long enough to give some decent results. The trial reporting on Thursday is only over 3 months I think which doesnt seem at long enough to take results that would be meaningful
This is the problem. They make claims that the disease (Parkinson's) is gradual and occurs over several years if not 10 years before any indications that a person has become a victim. So how can they think that the disease can modified in such a short time frame in a trial?
This is why I am convinced that the cure has already being found. But the studies were probably cut short because the end results did not justify continuing the studies. Perhaps a cure was discovered 10 years ago or more recently, from one of those thousand clinical trials.
Science and big Pharma are impatient sometimes, they use drug trials like a microwave cooking food, quick fix and time is minimal. When using an oven and cooking slowly gets a better result.
"This is why I am convinced that the cure has already being found. But the studies were probably cut short because the end results did not justify continuing the studies" - that is a very interesting comment. I have thought the same.
I agree. So in a way you are saying it might be beneficial to do these kind of studies where the results are tailored in a way that the drugs hits market as soon as possible. Later, users will tell it is more or less disease modifying ?
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease
Traditional Chinese Medicine Improves Activities of Daily Living in Parkinson's Disease
Caloric vestibular stimulation for the management of motor and non-motor symptoms in Parkinson's disease
NLY01 Phase II (modified Exanatide) - Recruiting in Michigan
